Member Info for oscar22

In this compelling interview, Tim McCarthy, CEO of ImmuPharma, shares exciting updates on the company’s transformative journey and plans for 2025. Key insights into their groundbreaking P140 platform can be found from minute 56 to 124, available here https://youtu.be/MlVnU6Eb4hg?si=NfVtNXyHNo3U1XEo

1. Revolutionary Advancements with P140

- Unprecedented Autoimmune Insights:

Tim has outlined that ImmuPharma’s P140 platform is on the brink of transforming the autoimmune sector. This platform is not merely progressing—it’s leading a revolution in diagnosing and treating diseases like lupus with groundbreaking precision and depth. The platform promises to refine how autoimmune disorders are identified and managed, heralding a new era in personalised medicine.

2. Strategic Financial Catalysts

- Major Licensing Agreements:

Tim’s discussions hint at imminent partnerships poised to inject substantial non-dilutive capital into ImmuPharma. These partnerships are expected to secure financial stability and accelerate the company's entire portfolio. Tim's confidence in these “substantial” deals reflects a potential windfall in the tens of billions, underscoring the transformative financial landscape awaiting ImmuPharma.

3. Diagnostic Innovations Set to Change Medical Landscapes

-Cutting-edge Diagnostic Tools:

With the advent of pioneering diagnostic technologies, ImmuPharma is setting the stage to redefine autoimmune treatment standards. These innovations are expected to enable earlier, more precise diagnoses, shifting towards highly personalised therapeutic regimens.

4. Delivering Promises in 2025

-A Year of Tangible Achievements:

Tim emphasises that 2025 will be marked as a 'transformative year'—a period when ImmuPharma transitions from potential to actualisation. Investors are encouraged to anticipate not just progress but also the unveiling of hidden gems within the portfolio that could dazzle the market.

5. Sustained Growth and Market Expansion

- Empowered by Strategic Partnerships:

The incoming partnerships and their resultant funding are slated to foster a self-sustaining growth model for ImmuPharma. This financial autonomy will eliminate the need for external funding rounds, allowing for continuous reinvestment into burgeoning projects and the exploration of new medical frontiers.

Conclusion: A Pioneering and Exciting Future for ImmuPharma

As Tim propels ImmuPharma through a pivotal year, the focus is sharply on delivering groundbreaking treatments and securing the company’s place as a leader in the biopharmaceutical sector. With a robust strategy and promising partnerships, 2025 is set to be a stellar year for ImmuPharma and its shareholders.

This information is provided for general informational purposes only and should not be considered as investment advice.

Tim McCarthy, CEO of ImmuPharma, gave an engaging and forward-looking interview yesterday that brought to light the transformative journey ImmuPharma is embarking on this year. Here’s, a summary in my opinion, highlighting the most exciting prospects for investors https://www.youtube.com/watch?v=xEW1hRom9Eg:

2025: The Year of Delivery

-Transformative Developments: Tim described 2025 as a "transformational year" for ImmuPharma, emphasising that it will be the "year of delivery." These terms underscore the significant advancements and strategic executions planned for the upcoming months, signalling major milestones that shareholders can eagerly anticipate.

Revolutionising Autoimmune Treatment with P140

- Groundbreaking Preclinical Results: The recent preclinical studies on the P140 platform have yielded revolutionary insights into autoimmune diseases. These findings are expected to drastically enhance diagnostic capabilities, making it possible to identify and treat autoimmune conditions with unprecedented precision.

- Personalised Medicine on the Horizon: ImmuPharma is at the forefront of developing personalised treatments that could significantly improve patient outcomes. The data from these studies are setting the stage for tailored therapies, a breakthrough in medical treatment.

Strategic Business Moves and Partnerships

-Engagement with Big Pharma: Tim highlighted active and advanced discussions with potential big pharma partners, brought into sharper focus with the compelling data from recent studies. These partnerships are likely to provide substantial non-dilutive funding, crucial for sustaining growth without diluting shareholder value.

Enhanced Diagnostic Tools

-Innovative Diagnostic Developments: A major takeaway from the recent work is the development of novel diagnostic tools that could become industry standards. These tools promise to identify autoimmune diseases with a level of accuracy previously deemed unachievable, representing a leap forward in medical diagnostics.

Promising Industry Engagement

-Impact of Industry Conferences: Insights from the JP Morgan conference highlighted the strategic timing of ImmuPharma's announcements, aligning with significant industry events to maximise impact and engagement with key stakeholders.

Looking Ahead: A Promising Future for Shareholders

-Optimistic Outlook for Investors: With the company pivoting towards delivering on its promises, Tim’s discussion radiates confidence in the strategic direction ImmuPharma is taking. The emphasis on upcoming "hidden gems" within our portfolio suggests exciting developments that could surprise and delight investors.

Conclusion

This year is poised to be pivotal for ImmuPharma, with Tim steering the company towards groundbreaking achievements in autoimmune therapies. For investors and industry watchers alike, ImmuPharma represents a beacon of innovation and potential in the biopharma sector, promising not just to

Hi Dallo,

Yes, the interview is indeed 10 months old, but as Tim emphasised, it's essential for us as investors to continually revisit the information the company provides, including RNS updates and interviews. This diligent approach helps us fully grasp the strategic roadmap that ImmuPharma is executing and helps to avoid misinformation or misleading rumours in this board. Today's RNS, with its groundbreaking findings on the P140 program for autoimmune diseases like SLE, is a testament to this strategy. It not only builds on the insights Tim shared previously but also highlights the significant strides we are making towards innovative treatments.

These recent findings could significantly enhance diagnostics and treatment efficacy, pushing ImmuPharma to the forefront of personalized medicine in this sector. Moreover, the new data could accelerate our discussions with potential partners, which Tim mentioned in his interview 10 moths ago. Given the advanced stage of these talks, we can expect the new insights to strengthen our position in negotiations, increasing the likelihood of finalising a substantial deal soon.

Tim was clear about the company's strategic focus on funding operations through partnerships that are expected to be non-dilutive. This aligns perfectly with our financial strategy to protect shareholder value and positions us well for future success.

Let's stay tuned for more updates and hopefully, a new interview from Tim soon to give us further insights into this exciting phase.

Kind regards, Oscar

Dallo,

Regarding the potential for a predatory takeover of ImmuPharma, it’s important to consider several protective factors inherent in biotech companies like ours. Firstly, the true value of a biotech firm often lies in its intellectual property and proprietary data, which aren't easily appraised through standard financial metrics. This complexity can act as a deterrent to potential hostile takeovers, especially if the suitor cannot fully evaluate the intrinsic value or the development stage of the underlying assets.

Moreover, biotech companies frequently have intricate agreements and collaborations involving licensing and co-development, which can complicate transfer of ownership rights. ImmuPharma's collaboration with entities like Avion could involve specific clauses that protect against abrupt changes in control, ensuring that ongoing projects like the development of P140 are safeguarded against hostile bids.

Given these nuances, any significant corporate move would likely need clear internal endorsements and might be structured to ward off unsolicited bids. If you’re looking for a deeper understanding of our corporate defenses against such scenarios, I highly recommend discussing this directly with Lisa or Tim. They can provide detailed insights specific to ImmuPharma’s strategic preparations and corporate governance.

It’s crucial to stay informed through official channels and keep an optimistic but critical eye on how these developments unfold. I remain confident in our long-term prospects and believe our current position is significantly undervalued, offering substantial growth potential as our projects progress. MAKE SURE YOU WATCH TODAY'S INTERVIEW: https://www.youtube.com/watch?v=jR7I_0mkTM4

Best regards, Oscar

CauldStream7

I always enjoy reading your posts, as well as Dallo's. Your experiences and insights are invaluable to this community. Regarding your point about past opportunities, it’s a common sentiment in the world of investing, and it's the thoughtful reflections that help us all grow and refine our strategies.

With today's RNS from ImmuPharma, I truly believe we are on track to see our patience rewarded. We have a winning team and the latest breakthrough findings provide a robust foundation not just for the upcoming trials but also in attracting big pharmaceuticals as potential partners. The enhanced understanding and solid data around our P140 therapy make ImmuPharma an even more attractive partner in the biotech field.

Looking ahead, the partnership with Avion adds an additional layer of optimism. Their involvement should help steer our trials towards success with more precision. As we await further updates on partnerships and trial progresses, the future does indeed look bright. This is an exciting time for all of us invested in ImmuPharma's journey.

Best regards, Oscar

Previous post: Key Takeaways from Today’s RNS Announcement:

1. Innovative Breakthroughs:

• ImmuPharma’s new insights into autoimmune disease pathogenesis, especially SLE, have led to the identification of pivotal biomarkers and pathways. This understanding facilitates:

• Improved Trial Design: More targeted clinical trials, selecting patient populations that are likely to see significant benefits, enhancing trial efficacy.

• Enhanced Patient Selection: Personalized medicine approaches that increase treatment success rates and reduce associated time and costs.

2. Impact on Regulatory Approval and Market Potential:

• Regulatory Success: Deeper mechanism insights aid in informed discussions with regulatory bodies, streamlining the approval process.

• Market Differentiation: P140’s non-immunosuppressive nature sets it apart, offering a significant advantage by avoiding common side effects of current treatments, potentially leading to strong market acceptance and premium pricing.

3. Intellectual Property and Commercial Strategy:

• Strengthening IP Portfolio: Expanding P140’s IP not only protects the therapy but also significantly enhances ImmuPharma’s valuation.

• Licensing and Partnerships: Strong patents and promising trial results position ImmuPharma to attract partnerships that could alleviate financial and logistical challenges and broaden market reach.

4. Leadership and Team Commitment:

• Led by Tim McCarthy, with key contributions from Lisa Baderoon, the team’s efforts in advancing P140 and navigating complex development phases are commendable. Their dedication positions the company well for future success. Although progress has taken longer than anticipated, we are certainly on the right track with a winning team poised for success.

Wishing all the best to my fellow long-term investors.

Key Takeaways from Today’s RNS Announcement:

1. Innovative Breakthroughs:

• ImmuPharma’s new insights into autoimmune disease pathogenesis, especially SLE, have led to the identification of pivotal biomarkers and pathways. This understanding facilitates:

• Improved Trial Design: More targeted clinical trials, selecting patient populations that are likely to see significant benefits, enhancing trial efficacy.

• Enhanced Patient Selection: Personalized medicine approaches that increase treatment success rates and reduce associated time and costs.

2. Impact on Regulatory Approval and Market Potential:

• Regulatory Success: Deeper mechanism insights aid in informed discussions with regulatory bodies, streamlining the approval process.

• Market Differentiation: P140’s non-immunosuppressive nature sets it apart, offering a significant advantage by avoiding common side effects of current treatments, potentially leading to strong market acceptance and premium pricing.

3. Intellectual Property and Commercial Strategy:

• Strengthening IP Portfolio: Expanding P140’s IP not only protects the therapy but also significantly enhances ImmuPharma’s valuation.

• Licensing and Partnerships: Strong patents and promising trial results position ImmuPharma to attract partnerships that could alleviate financial and logistical challenges and broaden market reach.

4. Leadership and Team Commitment:

• Led by Tim McCarthy, with key contributions from Lisa Baderoon, the team’s efforts in advancing P140 and navigating complex development phases are commendable. Their dedication positions the company well for future success. Although progress has taken longer than anticipated, we are certainly on the right track with a winning team poised for success.

Wishing all the best to my fellow long-term investors—here’s to our continued success with ImmuPharma! Looking forward to upcoming partnership announcements and trial updates. Holding 7.5 million shares, my only regret is not buying more. However, I plan to increase my investment when the opportunity arises.

NB: This is my personal opinion and not financial advice. Consult a professional

Hi Dallo, I agree with you, combining the value of the direct shares and the potential from the warrants can result in a net unrealised gain for ImmuPharma, especially considering the upside potential of the warrants.

Let's delve into how these warrants could significantly contribute to ImmuPharma's value, especially with Incanthera's growth trajectory and potential acquisition scenarios.

Understanding the Warrants

ImmuPharma holds 7.3 million warrants in Incanthera, exercisable at any time, which is a testament to ImmuPharma's strategic investment acumen. These warrants represent a right but not an obligation to purchase additional shares at a predetermined price, in this case, 9.5p. Given Incanthera's top share price of 18p this morning, these warrants already hold considerable unrealised value.

Current Value and Future Potential

-Current Value Analysis:

Incanthera Share Price: 18p

Warrant Exercise Price: 9.5p

Difference: 8.5p per share

With 7.3 million warrants, this difference suggests an immediate potential unrealized gain of approximately £620,500 for ImmuPharma, should these warrants be exercised at 18p. This calculation alone highlights the immediate upside potential.

-Future Growth Potential:

Incanthera's journey, particularly with its expanding portfolio and promising revenue projections, speaks volumes about its market potential. A takeover scenario, where Incanthera could be valued at, let's speculate, 100p per share, would dramatically increase the value of ImmuPharma's position.

Takeover Scenario Value:

Hypothetical Takeover Price: 100p

Gain per Warrant: 90.5p (after deducting the exercise price of 9.5p)

Total Gain from Warrants: £6,606,500 (Let's bear in mind the unused tax losses of £49,025,230 as of 31.12.2022 available for offset against future profits)

This speculative analysis does not just reflect the potential financial windfall but underscores the strategic importance of holding these warrants. The anticipation of Incanthera's growth, coupled with the biopharmaceutical sector's dynamism, where acquisitions are frequent for promising companies, makes this scenario a thrilling possibility.

Looking Ahead

ImmuPharma's investment in Incanthera, including its significant warrants holding, is a pivotal part of its long-term growth strategy. The biopharmaceutical industry is ripe with innovation and consolidation, making the potential for Incanthera's acquisition at a premium not just bullish but a plausible future event. This not only could result in substantial financial gains for ImmuPharma but also validate its strategic investment approach.

For long-term investors in ImmuPharma, this scenario paints a picture of significant upside potential, not just from its core operations but also from savvy investment decisions. The anticipated developments in Incanthera, from commercial success to possible acquisition offers, represent an exciting horizon.

This is my personal opinion, n

Financial Upswing for ImmuPharma

Value Appreciation: ImmuPharma's 10.8% stake in Incanthera is poised for growth, fueled by Incanthera's notable commercial achievements. This uptick enhances ImmuPharma's financial outlook.

Warrant Holdings: ImmuPharma also holds 7.3 million warrants in Incanthera, providing a further opportunity to benefit from Incanthera's positive momentum.

Commercial Success and Strategic Expansion

Revenue Projection: Incanthera's forecasted revenues, growing from £10m in FY 2025 to £33m in FY 2026, denote a trajectory towards substantial profitability. This financial health reflects positively on ImmuPharma's strategic investment decisions.

Market Expansion: The recent commercial success of Incanthera's skincare deal with Marionnaud, marked by the rollout of Skin + CELL across European and potentially Asian stores, signifies not just a strong market demand but also shines a favorable light on Incanthera and, by extension, ImmuPharma. Given that Dr. Tim McCarthy serves as CEO for both ImmuPharma and Incanthera, this achievement could potentially open new doors for ImmuPharma. The visibility and industry connections gained through Incanthera's success might facilitate new contacts and partnership deals for ImmuPharma. This could enhance ImmuPharma's visibility in the biopharmaceutical sector, potentially leading to collaborations that could accelerate the development and commercialisation of its innovative therapeutic solutions.

Enhanced Stakeholder Confidence

Market Performance: The positive performance of Incanthera's stock, with a significant increase of 94%, not only bolsters investor confidence but also showcases the potential for further growth and the soundness of ImmuPharma's investment.

Portfolio Diversification: ImmuPharma's involvement with Incanthera diversifies its investment portfolio, mitigating risks and aligning with long-term growth strategies in both biopharmaceuticals and related sectors. Under Tim McCarthy's leadership, ImmuPharma has shown a strategic approach towards growth and diversification, especially evident in the Incanthera investment. This move, once heavily critiqued by some investors, is now demonstrating its value, illustrating McCarthy's foresight and deal-making acumen. The success with Incanthera not only reflects positively on McCarthy's vision but also promises to elevate ImmuPharma's standing, potentially opening new doors for partnership and visibility. As we witness these developments, it's clear that ImmuPharma is in a strong position, poised for progress, and in its best shape in years, despite current market valuations.

Looking ahead, ImmuPharma is well-positioned to enhance long-term shareholder value, embracing new opportunities and challenges with a strategic focus on sustainable growth.

Disclaimer: The above represents my personal opinion and should not be considered financial or investment advice.

The biopharmaceutical landscape is witnessing a significant shift towards investments in rare disease therapies and companies focused on addressing unmet medical needs, highlighted by AstraZeneca's recent acquisition of Amolyt Pharma for up to $1.05bn. This deal underlines the growing interest in specialised therapeutic areas and positions companies like ImmuPharma at the forefront of industry trends, especially in autoimmune diseases and anti-infectives.

ImmuPharma is making notable strides in the field with its leading asset, Lupuzor, now progressing into a Phase 3 pivotal study for Systemic Lupus Erythematosus (SLE). This advancement is made possible through a strategic partnership with Avion, aimed at funding and potentially commercialising Lupuzor in the U.S. market. Lupuzor offers a unique mechanism aimed at "restoring" the immune system, setting it apart as a treatment with the potential to establish new standards in autoimmune disease management.

Furthermore, ImmuPharma's commitment to combating the challenge of increasing resistance to existing anti-infective treatments is evident in its development of innovative solutions like BioAMB and BioCIN. The company's targeted approach to anti-infectives meets a critical global health need, potentially unlocking significant market opportunities.

The journey of Amolyt Pharma, culminating in its acquisition, serves as an illustrative benchmark for ImmuPharma's potential trajectory. ImmuPharma's diversified focus across autoimmune, inflammatory conditions and anti-infectives demonstrates its broad-spectrum approach and adaptability, enhancing its attractiveness to investors and partners.

Overall, ImmuPharma distinguishes itself in the biopharmaceutical sector with its innovative drug development strategies, strategic alliances, and commitment to addressing critical medical needs. The company's ongoing projects and strategic direction suggest a promising future, potentially positioning it as a key player within the global biopharma community. For further details on ImmuPharma's advancements and strategic objectives, their official website and investor presentations offer comprehensive insights.

Despite ImmuPharma's low share price, a hostile takeover is unlikely. The company's unique focus and proprietary knowledge in biopharmaceuticals present substantial challenges to unsolicited acquisitions. ImmuPharma's strategic defences, including shareholder rights plans, coupled with its invaluable internal expertise, act as significant deterrents. Any future acquisition or partnership is expected to be friendly and value-driven, reflecting the company's true worth and aligning with shareholder interests, ensuring the preservation of ImmuPharma's innovative vision and maximising value.

Disclaimer: This is my opinion. Do your research. ATB to loyal long-term holders.

Immupharma's presence at BIO-Europe Spring 2024 in Barcelona reflects a strategic and visionary approach from the board, highlighting the company's commitment to growth and innovation. By participating in this premier event, Immupharma seizes a critical opportunity to network with global biopharma leaders, showcasing its advanced projects like the P140 platform for SLE (Lupuzor) and the promising anti-infective asset, BioAMB. This engagement underscores the company's ongoing negotiations and pursuit of the best partnerships, signaling a robust and forward-moving trajectory.

- Explore BIO-Europe Spring 2024's significance (https://flanders.bio/en/events/bio-europe-spring-2024) (https://www.biotech.ca/event/bio-europe-spring-2024-18th-annual-international-partnering-conference/)

BIO-Europe Spring serves as an unrivaled forum for biotech companies, attracting over 3,700 leading executives and facilitating more than 20,000 partnering meetings. This proactive engagement demonstrates the company's commitment to enhancing its portfolio through strategic alliances and partnerships, highlighting its readiness to leverage every opportunity for growth. Far from a mere effort to attract attention, this move exemplifies Immupharma's dedication to advancing its ongoing discussions with potential partners, offering a comprehensive view of its potential to stakeholders worldwide.

- Learn about the event and its global reach (https://informaconnect.com/bioeurope-spring/)

The decision to attend BIO-Europe Spring is aligned with Immupharma's strategic vision, demonstrating the board's proactive efforts to position the company at the forefront of the biotech industry. It reveals a commitment not only to advancing current negotiations but also to seek new opportunities that could enhance the company's projects and shareholder value. This proactive approach in global forums like BIO-Europe Spring highlights Immupharma's dedication to making significant strides in drug development and partnerships, debunking any misconceptions about its business development activities being stagnant.

Immupharma's participation at BIO-Europe Spring 2024 is an integral component of its strategy, leveraging the event's extensive network and collaborative opportunities. This engagement is a clear indication of the company's active pursuit of partnerships and investments, reinforcing the management's dedication to driving growth and innovation within the biotech sector.

"Opportunities don't happen, you create them." — Chris Grosser

Disclaimer: This is my opinion. Do your research. Best wishes to loyal long-term holders.

Hi Dallo,

You're spot on with your explanation. It matches UK's clear rules for shareholders of UK-listed companies like Immupharma, regarding the need to announce changes in their stakes. Lanstead, holding 15.89% as per the 28 December 2023 RNS, would need to issue notifications for any sale altering their position, for example:

-A sale reducing their stake by 1% to 14.89%.

- A 2% sale leading to a stake of 13.89%.

- Dropping to a 10% stake through significant sales.

This transparency maintains market integrity. For specifics, see the FCA Handbook DTR 5. FCA Handbook DTR 5 https://www.handbook.fca.org.uk/handbook/DTR/5/1.html.

Wishing all the dedicated and visionary long-term holders the very best.

Moneymule888,

Your latest volley of comments only solidifies your position as disconnected from the realities of biotech innovation and the strategic direction of Immupharma. It’s clear now; your approach is not about engaging in constructive critique but peddling unfounded skepticism.

Claiming "there is no product and there never will be" showcases a blatant disregard for Immupharma's documented progress and development pipeline. Your fixation on doom, notably the baseless prediction of Phase III failure, betrays a superficial understanding of the biotech sector and the intricacies of AIM-listed companies.

Your narrative, stripped of substance and clinging to cynicism, has been thoroughly discredited by the facts at hand. It’s evident your commentary stems not from informed analysis but a penchant for spreading discord without merit.

The real laughable aspect here is not Immupharma’s potential or its strategic pursuits but your persistent denial of documented advancements and the broader biotech investment landscape's complexity. As your misleading assertions crumble under the weight of facts, your stance becomes increasingly untenable, revealing a profound lack of understanding of the sector you critique.

Moneymule888:

Your continuous dissemination of unfounded narratives around Immupharma necessitates not just a rebuttal, but a decisive correction based on the facts laid out in Immupharma's RNS dated 6 March 2024. Your comments, riddled with inaccuracies, showcase a significant misunderstanding of Immupharma’s strategic positioning, financial health, and advancements, calling for a precise, fact-based clarification.

1. Immupharma's Progress:

Your Assertion: Immupharma has achieved little, with Incanthera as its sole asset of value.

Fact-Check (RNSs including 6 March 2024): This portrayal grossly undermines Immupharma's strategic advancements. The company's development pipeline, especially P140 (Lupuzo) for SLE/Lupus and CIDP, demonstrates a dynamic and robust approach to addressing unmet medical needs. Further, the RNS explicitly highlights active discussions for non-dilutive funding through potential lucrative deals, showcasing proactive financial strategy and execution far from the stagnation you suggest.

2. On Financial Stability:

Your Assertion: Imminent bankruptcy and financial distress loom over Immupharma.

Fact-Check (RNS, 6 March 2024): Contrary to your false and doom-laden forecast, Immupharma explicitly confirms its sufficient financing position for its immediate requirements, with no current plans to raise equity in the capital markets. The company's strategic focus on non-dilutive income further solidifies its financial health, directly countering your narrative of fiscal instability.

3. On the Board’s Efforts:

Your Assertion: The board's efforts are portrayed as ineffective.

Fact-Check (RNS, 6 March 2024): The RNS details a strategic reorganisation and significant cost reductions that have notably strengthened Immupharma’s operational and financial standing. These actions reflect a board effectively navigating the company towards sustainable growth and innovation, contrary to your claims of mismanagement.

4. A Call to Responsible Discourse

Your dissemination of misinformation not only undermines factual discourse but potentially harms the broader investor community. The implications of spreading such baseless claims are severe, underscoring the need for accountability in public communications about publicly traded entities.

If your interpretation of Immupharma’s strategic direction and progress remains misaligned with the clear, documented evidence presented by the company, it may be time to reevaluate your engagement. For those of us committed to Immupharma's future, we remain focused on the promising path ahead, underpinned by innovation, strategic growth, and factual, transparent communication.

Finally a Jeff Bezos's words, "the stock is not the company and the company is not the stock". Though Immupharma is clearly not Amazon, this principle remains relevant, emphasising the importance of distinguishing Immupharma's intrinsic value from its stock performance. https://youtu.be/zzWh26xmy

Dear long-term Shareholders,

As someone deeply invested in ImmuPharma, with a substantial holding of 9 million shares, I am eager to express my enthusiasm for our company's recent landmark announcement. This update isn't just news; it's a testament to the strategic foresight and unwavering commitment of our team.

Robust Financial Footing & A Promise of No Further Dilution

We've reached a pivotal moment where ImmuPharma's financial health is stronger than ever, confirmed by our strategic avoidance of equity fundraising in the near term. Our financial prudence, combined with active engagements to secure non-dilutive income from our rich asset portfolio, including P140 for Lupus and BioAMB, signifies a future ripe with opportunity and growth.

Operational Excellence: Streamlined for Success

A staggering reduction of operational costs by over 75% reflects the commitment to lean and focused operations. This remarkable achievement has not only optimised the resource allocation but also underscores the capability to direct our energies toward pivotal projects. ImmuPharma now operates with unparalleled efficiency, setting a new standard in the biotech industry.

Strategic Alliances: Broadening Horizons with Avion

Our collaboration with Avion and ongoing discussions for Lupuzor's non-US rights showcase the power of strategic partnerships. Avion's support and the anticipated updates on this collaboration promise to catapult us into new realms of possibility and success.

Pioneering Developments: P140 & Beyond

The advancements in our P140 Lupuzor Phase 3 study, led with precision by Simbec-Orion, underscore its groundbreaking potential. This, along with the CIDP program's momentum, illuminates our path towards revolutionising autoimmune disease treatment.

Incanthera Investment: A Goldmine Awaiting Unveil

Our stake in Incanthera has proven to be a strategic masterstroke. With Incanthera's trajectory set for a spectacular year, marked by their recent triumphs detailed in their RNS announcements, we stand on the cusp of realising significant gains from this investment.

A Note of Appreciation and A Call to Vision

A massive thanks goes to Tim McCarthy, Lisa Baderoon, and the entire ImmuPharma team for steering our ship with courage and foresight. Their relentless pursuit of excellence has not only weathered storms but also prepared us for a dawn filled with success and prosperity.

In closing, ImmuPharma isn't just navigating the present; we're crafting a future where our strategic decisions today will forge a legacy of innovation and success. My confidence in our journey forward is unshaken, and I eagerly anticipate the unfolding of our collective aspirations.

IImmuPharma is not a haven for the short-sighted or the ill-informed seeking quick gains. It's a realm for the sophisticated investor, for those with clever vision and knowledge, who recognise the untapped value of this hidden gem.

This letter offers personal i

@CauldStream7, your summary of the agreement is much appreciated.

@Pokerchips, for a thorough understanding, I would suggest reviewing the official announcements from Immupharma before forming and sharing any opinions.

Let’s delve into the recent discussions surrounding the collaboration between Immupharma (IMM) and Avion Pharmaceuticals on the Lupuzor trial. It is essential to understand the dynamics of this partnership and its potential implications for our investments.

At the heart of this relationship lies a strategic alliance between IMM and Avion, characterized by mutual benefits and shared responsibilities. While Avion is providing the funds for the forthcoming Lupuzor trial, this financial backing should not be perceived as a unilateral acquisition of the trial's data and results. In fact, it embodies Avion's profound interest in the success of this trial, especially considering the prospective market window in the US.

IMM holds a pivotal position in this partnership. This collaboration is not merely a transactional exchange; it represents a symbiotic relationship where benefits accrue for both parties. Not only does IMM provide Avion with the exclusive rights to commercialize Lupuzor in the US, but both organisations will also collaboratively share consequential data, insights, knowledge, and expertise.

For Immupharma, the benefits of this data sharing are manifold. Access to this collective data will enable IMM to refine its strategies, optimise its offerings, and make informed decisions, laying the groundwork for its future ventures and this is invaluable.

Further, as investors, it is paramount to acknowledge that Immupharma stands on the cusp of significant financial gains should outcomes prove successful. With Lupuzor's FDA approval and subsequent robust sales performance, we can anticipate a cascade of payments that will augment IMM's financial position, extending beyond the immediate benefits derived from the trial data.

This partnership goes beyond the simple boundaries of outsourcing. Immupharma and Avion are both deeply involved in every step of Lupuzor's development journey, actively participating in thorough discussions about the trial’s structure, the methods employed, and the expected results. Their united dedication enhances Lupuzor's stature, positioning it as a prominent contender in the field of lupus treatment.

In conclusion, we should recognise this partnership for what it truly represents: A strategic alliance filled with potential, not just for Lupuzor but also for Immupharma's broader growth objectives. As we navigate our investment path, collaborations of this nature offer a strong foundation for our confidence and optimism.

The aforementioned views represent my analysis based on current data and are not to be construed as investment guidance.

Avion Pharmaceuticals has entered into an exclusive license and development agreement with ImmuPharma for Lupuzor, targeting the US market. Committed to advancing this promising drug, Avion is financing up to $25 million for an international Phase 2/3 adaptive study and is actively supporting ImmuPharma in identifying potential partners globally. This crucial study seeks to validate the clinical pharmacology and pharmacokinetic profiles of Lupuzor, setting the stage for the decisive Phase 3 trial, while aligning with previous FDA submissions regarding study protocols and regulatory pathways.

Lupuzor has garnered attention with its encouraging results in past lupus trials, securing fast-track designation from the FDA. Avion's strategic focus on women's health, dermatology, and rheumatology, combined with its profound understanding of the US pharmaceutical landscape, positions it as a key player in this venture, particularly relevant given lupus's pronounced impact on women, often during their childbearing years, manifesting in skin rashes and joint inflammation.

Art Deas, at the helm of Alora, Avion's parent company, embodies the deep conviction behind this collaboration. Alora's holding of 10,909,091 shares of IMM, comprising 2.61% of the issued share capital, reflects a serious commitment. This dedication echoes through Avion's pledged financial backing for Lupuzor, entailing $5 million upon approval, potentially escalating to $70 million relative to US sales achievements, alongside royalties of up to 17% on specific sales figures.

For Alora, the implications of this venture are profound. Retracting from their commitment would necessitate surrendering Lupuzor’s exclusive US rights, jeopardizing their esteemed standing in the specialty pharmaceutical realm. Beyond the potential tarnish to their reputation, such a move would also mean Alora passing up on an expansive financial opportunity within the US lupus market, projected to burgeon to $3.6 billion by 2029, coupled with substantial financial losses. Achieving regulatory approval for Lupuzor in the US isn't merely about immediate profitability; it embodies the addition of a prospective blockbuster to Alora’s distinguished portfolio, heralding continuous and substantial revenue growth.

Alora's pharmaceutical successful portfolio is indeed noteworthy. It incorporates six specialty pharmaceutical entities, each with an array of approved products across diverse therapeutic categories. Among their innovative breakthroughs is voxelotor for sickle cell disease, granted FDA’s accelerated approval in 2019 following its positive impact on hemoglobin levels.

In summary, the strategic alliance, fortified by Lupuzor's potential, heralds a bright horizon. Their combined expertise and strategic foresight are steering towards transformative milestones for Lupuzor, potentially redefining standards in lupus treatment.

The above represents my analysis and is not to be construed as investm

@ Lordsloadsoflolly,

I appreciate your engagement on this topic and the opportunity to offer a deeper perspective on the Lanstead Sharing Agreement based on the latest RNS from Immupharma.

1. Benchmark Price:

The Benchmark Price, as detailed in the RNS, is set at 2.6667 pence per ordinary share. This serves as the foundational reference for the monthly adjustments.

2. Upside Potential:

It's essential to note that should Immupharma's share price consistently outperform this Benchmark Price, the company is positioned to gain significantly. In essence, if the share price is on an upward trajectory, Immupharma will receive more than the originally agreed amount for that period. I'm hopeful that we'll receive some updates in the coming weeks, particularly concerning the CRO appointment. In addition, news of potential strategic collaborations, such as with Avion for distributing Lupuzor outside the US, could cause a significant increase in the share price. Remember, good partnerships take time to form. Immupharma wants to make sure they choose the right strategic partner that fits well with everyone, including Avion. That's why it's taking a bit longer than expected.

3. Aligned Interests:

While the structure of the agreement might appear to lean towards Lanstead, it's fundamentally designed to align the interests of both parties. If Immupharma's share price excels, both Immupharma and Lanstead stand to benefit. Conversely, if the share price faces challenges, both parties absorb the implications, thereby sharing the downside.

4. Lanstead's Involvement:

It's worth emphasising that it would be counterintuitive for a major shareholder like Lanstead to wish for Immupharma's decline. Their investment strategy is not anchored in short-term gains but rather in the long-term potential and growth of the companies they invest in. As such, Lanstead's involvement is more about collaborative risk management and capitalising on the shared growth prospects.

To conclude, from an investor's perspective, the agreement represents a strategic partnership. It fosters mutual benefits, encouraging both entities to work towards a shared objective: the sustained and robust performance of Immupharma's shares.

The aforementioned views represent my analysis based on current data and are not to be construed as investment guidance.

@dallo,

Thank you for your insights and the opportunity to discuss the resilience and prospects of ImmuPharma in these turbulent times.

1, Global Uncertainties:

The current geopolitical situation, particularly the tensions in Israel, is indeed concerning. However, historically, global markets have demonstrated remarkable resilience in the face of geopolitical strife. The extreme scenario of a third World War is highly improbable, and it's critical we maintain perspective and not allow these uncertainties to cloud our long-term investment strategies. Our thoughts and prayers go out to all those affected by the ongoing conflict, hoping for a swift resolution and peace for all involved.

2. Avion's Commitment:

The partnership between ImmuPharma and Avion is built on a foundation of mutual dedication towards advancing Lupuzor™ through its critical stages. Avion's notable investment, especially their active role in gearing up for Lupuzor's imminent clinical trials and the strategic appointment of a specialist CRO, underscores their unwavering commitment. This active engagement not only highlights their belief in Lupuzor's promise but also makes it improbable for them to reconsider their stance now. It's evident they grasp the transformative potential of Lupuzor and the substantial benefits it could bring to their portfolio.

3. Lupuzor Developments:

Recent updates from ImmuPharma have been promising, with the successful completion of the P140 Pharmokinetic (PK) study, indicating favorable safety, tolerability, and applicable dosing regimens for P140. Furthermore, the active preparation for a phase 2/3 clinical study for CIDP showcases the progress and breadth of applications for Lupuzor.

4. Strategic Partnerships & Transparency:

As Lupuzor garners attention globally, discussions with potential partners for its distribution outside the US are ongoing, promising a comprehensive reach upon successful trial completion. Rest assured, any material developments in these strategic discussions or changes in partnerships, as per regulatory standards, will be promptly communicated to investors through an RNS.

In conclusion, ImmuPharma stands on solid ground, with ongoing clinical trials, committed partnerships, funding, and a promising future for Lupuzor, despite the shadows cast by global events. My focus remains on the science and potential that has brought us all together in this journey.

The aforementioned views represent my analysis based on current data and are not to be construed as investment guidance.

@lordloadsoflolly,

Thank you for emphasising the nuances in my previous comment. In discussing ImmuPharma's journey, it's essential to distinguish between past challenges and present resilience.

1. Historical Context and Resilience:

Certainly, ImmuPharma's historical trajectory has had its challenges. However, setbacks, like the one in the P3 trial and other unexpected delays, serve not just as roadblocks but as crucial learnings. What stands out is the company's resilience to recalibrate and reposition itself. These challenges have fueled introspection, strategy refinement, and a more robust approach, reflecting a resilience and adaptability that's commendable.

2. Avion Pharmaceuticals' Alliance:

The partnership with Avion isn't merely a transaction—it's a strategic alignment. Avion's commitment signals a belief in ImmuPharma's potential, a belief that goes beyond historical data points. Their collaboration is anchored in the promising drug pipeline, scientific prowess, and a rejuvenated strategy. It underscores not only what ImmuPharma has achieved but, more critically, what it's poised to accomplish in the future.

2. Strategic Positioning and Financial Backing:

With the recent agreement with Lanstead and the support of other informed investors, ImmuPharma is not just resilient but funded. This financial positioning facilitates ongoing R&D, ensuring the company is well-placed to navigate the multifaceted demands of the biotech world.

3. Looking Ahead with Optimism:

While history offers lessons, my optimism is predicated on ImmuPharma's current and future prospects and strategy. The biotech landscape is dynamic, and a company's ability to evolve, learn, and grow is more indicative of its potential than past challenges. I look forward to the company's updates, confident that they will reflect the strategic strides being made.

To conclude, it's a blend of ImmuPharma's historical learnings, present resilience, and a future filled with promise that cements my optimism. We're witnessing a unique company in evolution, and I remain enthusiastic about the journey ahead.

The aforementioned views represent my analysis based on current data and are not to be construed as investment guidance.

@Lambo

In light of the RNS released on 31 August 2023 regarding Immupharma's agreements with Lanstead, based on my understanding, let me provide some clarity:

1. The Sharing Agreement:

The Sharing Agreement between Immupharma and Lanstead does revolve around the £1.0 million Lanstead subscribed for. However, it's not just a straightforward sell of shares into the market. Instead, Immupharma pledges this entire £1.0 million back to Lanstead. Over a 24-month period, Lanstead will make monthly settlements back to Immupharma. The unique feature here is that the amount Immupharma receives each month varies based on the company's share price. If the share price is above a certain Benchmark Price (2.6667 pence per ordinary share), Immupharma stands to receive more than the initially pledged amount for that month. Conversely, if the share price is below this Benchmark Price, the monthly amount they receive would be less.

2. Monthly Payments:

Regarding your query on how Immupharma gets its monthly payment if Lanstead doesn't sell shares: The Sharing Agreement, as mentioned, has a mechanism that provides payments to Immupharma based on share price performance. It doesn't specify that Lanstead must sell the shares to give Immupharma the monthly payment. The concept is that if Immupharma's share price performs well, the company benefits, which aligns the interests of both parties.

3. Benefits to Immupharma:

This agreement provides several benefits for Immupharma. It offers an immediate influx of cash, an opportunity to benefit from positive share price movements, and a strategic partnership with a significant shareholder, Lanstead.

In summary, the Sharing Agreement is more intricate than a simple sell of shares into the market. It's structured to provide both immediate funds and potential future benefits to Immupharma based on share price performance.

I hope this provides clarity on the nature of the Sharing Agreement and how it works. I suggest you do some proper reading so you understand better the info provided in the RNSs.

The aforementioned views represent my analysis based on current data and are not to be construed as investment guidance.